Skip to main content

Curanex Pharmaceuticals Inc

corporate_fare Company Profile

Curanex Pharmaceuticals Inc

CURX·NASDAQ·Life Sciences·CIK 0002025942

Curanex is a developmental stage pharmaceutical company focused on discovering, developing, and commercializing innovative botanical drugs for patients with inflammatory diseases. The company aims to address unmet medical needs by utilizing natural substances. Curanex is dedicated to developing botanical medicines for immune and inflammatory diseases, and therapies for autoimmune diseases, metabolic diseases, and viral infections. Its current drug development pipeline includes six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease ("NAFLD"), and gout. Curanex's lead drug candidate is Phyto-N, a proprietary botanical extract derived from a medicinal plant with a long history of human use in Chinese traditional medicine. Phyto-N has shown positive results in animal models of multiple inflammatory diseases. The company's research to date has been limited to preclinical studies for each of its indications. Curanex plans to submit an Investigational New Drug application ("IND") for the treatment of ulcerative colitis in the fourth quarter of 2026. If the U.S. Food and Drug Administration ("FDA") allows, a Phase I trial will begin 30 days after IND submission. Following positive Phase I results, the company intends to proceed with a Phase II trial for ulcerative colitis as its lead indication.

Curanex Pharmaceuticals Inc (NASDAQ:CURX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for CURX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CURX spans 10-Q, 8-K, DEF 14C, PRE 14C.

Recent high-impact activity:

  • Curanex 10-Q: $9.26M Nine-Month Loss, $1.58M Cash, Going-Concern Doubt
  • Second IPO Securities Class Action Hits Curanex; Auditor and Ex-CFO Named
  • Curanex 10-Q: Going Concern Doubt, 1-for-20 Reverse Split Set for Aug 20
  • Definitive Statement Filed for Reverse Stock Split and New Dilutive Equity Plan
  • Curanex Pharmaceuticals Approves Reverse Stock Split to Avoid Delisting, Adopts New Equity Incentive Plan

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$4.23M
Diluted EPS
-$0.17
Op. Cash Flow
-$10.48M
Operating Income
-$4.24M
Cash & Equivalents
$4.97M
Debt / Equity
0.00×
Shares Outstanding
28.34M sh
Source: 10-K · filed 2026-03-30 · accession 0001493152-26-013677

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 5,945 shares in CURX as of the October 30, 2026 settlement, a 14.4% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 29.1% of CURX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,945 shares as of October 30, 2026
Change vs prior period▲ 14.4%
Days to cover1.00 at avg daily volume of 13,269
Daily short volume (FINRA facilities)29.1% of 784 shares on November 19, 2026
5-day average short volume9.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$4.41 -0.67% today
52-week range · as of 2026-11-13 $3.58 – $13.33
Market cap
$6.92M
Volume
2.7K (0.3× avg)
3-mo avg 8.7K
Live data · 2026-11-20 23:31 UTC · After hours

show_chartPrice Chart

Loading chart...

feed CURX - Latest Insights

CURX
Nov 13, 2026, 1:41 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.64
Real-time Price: $4.41 info
Change: -$0.2296 (-5%) info
Market Cap: $6.916M info
CURX
Oct 19, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.92
Real-time Price: $4.41 info
Change: -$0.5096 (-10%) info
Market Cap: $6.916M info
CURX
Aug 14, 2026, 12:15 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.2162
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
Jun 29, 2026, 10:18 AM EDT
Filing Type: DEF 14C
Importance Score:
8
Price at Filing: $0.2835
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
Jun 18, 2026, 5:12 PM EDT
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.2705
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
May 14, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3278
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
May 14, 2026, 8:47 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.3185
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
May 07, 2026, 11:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3221
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
Apr 08, 2026, 7:47 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.490
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
Apr 06, 2026, 9:17 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.529
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
Apr 02, 2026, 8:07 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.510
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
Mar 18, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.3948
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
Mar 06, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3938
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
CURX
Jan 05, 2026, 3:47 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.384
Real-time Price: $4.41 info
Change: Reverse Stock Split info
Market Cap: $6.916M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets